Approval of Eli Lilly's Alzheimer Drug Donanemab Delayed as FDA Seeks More Information
Because of the unique trial design of the Phase III TRAILBLAZER-ALZ 2 study, the FDA is seeking additional input regarding the safety and efficacy of donanemab for the treatment of early symptomatic Alzheimer disease.
